{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:05:59Z","timestamp":1780747559892,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s12325-015-0212-6","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T06:37:28Z","timestamp":1432017448000},"page":"445-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon \u03b2-1a"],"prefix":"10.1007","volume":"32","author":[{"given":"Ali-Fr\u00e9d\u00e9ric","family":"Ben-Amor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Trochanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya Z.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"key":"212_CR1","unstructured":"Summary Safety Review\u2014Interferon-beta Products\u2014Thrombotic Microangiopathy. Health Canada; 2014. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/medeff\/reviews-examens\/interferon-beta-eng.php . Accessed Jan 20, 2015."},{"issue":"3","key":"212_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.msard.2013.12.007","volume":"3","author":"R Vosoughi","year":"2014","unstructured":"Vosoughi R, Marriott JJ. Thrombotic microangiopathy in interferon beta treated multiple sclerosis patients: review of literature and report of two new cases. Mult Scler Relat Disord. 2014;3(3):321\u20135.","journal-title":"Mult Scler Relat Disord."},{"issue":"7","key":"212_CR3","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/ndt\/gfs279","volume":"27","author":"T Barbour","year":"2012","unstructured":"Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27(7):2673\u201385.","journal-title":"Nephrol Dial Transplant"},{"issue":"18","key":"212_CR4","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMcp053024","volume":"354","author":"JN George","year":"2006","unstructured":"George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354(18):1927\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"212_CR5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.02699.x","volume":"113","author":"R Fuge","year":"2001","unstructured":"Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol. 2001;113(1):58\u201364.","journal-title":"Br J Haematol"},{"issue":"9","key":"212_CR6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/rheumatology\/kel224","volume":"45","author":"V Majithia","year":"2006","unstructured":"Majithia V, Harisdangkul V. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a frequent and severe consequence of active disease. Rheumatology (Oxford). 2006;45(9):1170\u20131.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"212_CR7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00062752-200109000-00004","volume":"8","author":"PJ Medina","year":"2001","unstructured":"Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001;8(5):286\u201393.","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"212_CR8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.smj.0000209275.75045.d4","volume":"99","author":"SS Sekhon","year":"2006","unstructured":"Sekhon SS, Roy V. Thrombocytopenia in adults: a practical approach to evaluation and management. South Med J. 2006;99(5):491\u20138.","journal-title":"South Med J"},{"key":"212_CR9","unstructured":"Rebif (interferon beta-1a) for subcutaneous injection. Highlights of Prescribing Information. EMD Serono Inc.; 2014. http:\/\/emdserono.com\/cmg.emdserono_us\/en\/images\/Rebif%20PI_Jun2014_tcm115_19765.pdf?Version= . Accessed Jan 20, 2015."},{"key":"212_CR10","unstructured":"Rebif solution for injection in cartridges. Summary of Product Characteristics. Merck Serono Ltd; 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000136\/WC500048681.pdf . Accessed Jan 20, 2015."},{"issue":"13","key":"212_CR11","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","volume":"370","author":"D Hunt","year":"2014","unstructured":"Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med. 2014;370(13):1270\u20131.","journal-title":"N Engl J Med"},{"issue":"3","key":"212_CR12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","volume":"158","author":"M Scully","year":"2012","unstructured":"Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323\u201335.","journal-title":"Br J Haematol"},{"issue":"13","key":"212_CR13","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1177\/1352458514523692","volume":"20","author":"C Larochelle","year":"2014","unstructured":"Larochelle C, Grand\u2019maison F, Bernier GP, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing\u2013remitting multiple sclerosis patients on high-dose interferon beta. Mult Scler. 2014;20(13):1783\u20137.","journal-title":"Mult Scler."},{"issue":"1","key":"212_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1191\/1352458502ms771sr","volume":"8","author":"J Reess","year":"2002","unstructured":"Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing\u2013remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy. Mult Scler. 2002;8(1):15\u20138.","journal-title":"Mult Scler."},{"key":"212_CR15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/DDDT.S42138","volume":"7","author":"J Mahe","year":"2013","unstructured":"Mahe J, Meurette A, Moreau A, Vercel C, Jolliet P. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther. 2013;7:723\u20138.","journal-title":"Drug Des Devel Ther."},{"key":"212_CR16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4137\/CMBD.S12843","volume":"6","author":"KZ Oregel","year":"2013","unstructured":"Oregel KZ, Ramdial J, Gluck S. Nonsteroidal anti-inflammatory drug induced thrombotic thrombocytopenic purpura. Clin Med Insights Blood Disord. 2013;6:19\u201322.","journal-title":"Clin Med Insights Blood Disord."},{"key":"212_CR17","doi-asserted-by":"crossref","unstructured":"Pollock K. Enhanced surveillance of haemolytic uraemic syndrome and other thrombotic microangiopathies (ENSHURE) in 2003\u20132004. Health Protect Scotland; 2005. http:\/\/www.documents.hps.scot.nhs.uk\/ewr\/pdf2005\/0518.pdf . Accessed Jan 20, 2015.","DOI":"10.2807\/esw.10.20.02708-en"},{"issue":"9139","key":"212_CR18","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"G Ebers","year":"1998","unstructured":"Ebers G, PRISMS (Prevention of Relapses and Disability by Interferon \u03b2-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet. 1998;352(9139):1498\u2013504.","journal-title":"Lancet"},{"issue":"12","key":"212_CR19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.56.12.1628","volume":"56","author":"PRISMS (Prevention of Relapses and Disability by Interferon \u03b2-1a Subcutaneously in Multiple Sclerosis) Study Group, the University of British Columbia MS\/MRI Analysis Group","year":"2001","unstructured":"PRISMS (Prevention of Relapses and Disability by Interferon \u03b2-1a Subcutaneously in Multiple Sclerosis) Study Group, the University of British Columbia MS\/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628\u201336.","journal-title":"Neurology"},{"issue":"6","key":"212_CR20","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1212\/01.wnl.0000237994.95410.ce","volume":"67","author":"L Kappos","year":"2006","unstructured":"Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing\u2013remitting MS. Neurology. 2006;67(6):944\u201353.","journal-title":"Neurology."},{"key":"212_CR21","unstructured":"Kappos L, Verdun di Cantogno E, Cornelisse P, Kuhle J, Uitdehaag B. Cumulative dose-effect of up to 15\u00a0years of subcutaneous interferon beta-1a on clinical outcomes in relapsing\u2013remitting multiple sclerosis: exploratory analysis of patients from the PRISMS study. J Neurol. 2012;259(Suppl 1):S110 [P470]."},{"issue":"9","key":"212_CR22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.clinthera.2007.09.025","volume":"29","author":"SR Schwid","year":"2007","unstructured":"Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29(9):2031\u201348.","journal-title":"Clin Ther"},{"issue":"5","key":"212_CR23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5414\/CN106523","volume":"76","author":"A Broughton","year":"2011","unstructured":"Broughton A, Cosyns JP, Jadoul M. Thrombotic microangiopathy induced by long-term interferon-beta therapy for multiple sclerosis: a case report. Clin Nephrol. 2011;76(5):396\u2013400.","journal-title":"Clin Nephrol"},{"issue":"11","key":"212_CR24","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1177\/1352458512441272","volume":"18","author":"PJ Modrego","year":"2012","unstructured":"Modrego PJ, Gazulla J. Arterial hypertension induced by interferon beta 1b in a patient with multiple sclerosis. Mult Scler. 2012;18(11):1655\u20136.","journal-title":"Mult Scler."},{"key":"212_CR25","unstructured":"Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome. Medicines and Healthcare Products Regulatory Agency; 2014. http:\/\/www.mhra.gov.uk\/home\/groups\/dsu\/documents\/publication\/con465961.pdf . Accessed Jan 20, 2015."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0212-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T04:18:47Z","timestamp":1566706727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0212-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0212-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}